November 2009 Grants
Altschuler, S., NIH, On the Emergence of Polarization and Motility Responses from Chemotactic Networks, $195,000; Boothman, D., DOE, Low Dose IR Activation of TGF-Beta-1-sCLU In Vivo: Mechanisms, Functions of Changing Microenvironment, $230,191; Carr, B., NIH, Contraceptive Efficacy Evaluation for the Path Female Condom, $209,420; Cleaver, O., NIH, Endothelial Signals During Organogenesis, $181,300; Crandall, C., NIH, Control of Skin Blood Flow and Sweating in Grafted Skin, $193,755 (supplement).
Diaz-Arrastia, R., NIH, Traumatic Brain Injury Clinical Trials Network, $269,446; Diaz-Arrastia, R., NIH/Columbia Univ. Med. Ctr., Genetic Consortium for Late-Onset Alzheimer’s Disease, $100,252; Eastman, A., NIH/Washington Univ., Establishing the Ethical Framework for Critical-Care Genetics, $57,173; Elmquist, J., NIH/Beth Israel Deaconess Med. Ctr., Peripheral and Central Interactions in Energy Balance-Project 1, $73,192; Forman, J., NIH, Immune Potential of Animal Lacking Class IA Molecules, $200,257.
Freeman, A., CDC, HIV Training Through Prevention Training Centers, $91,750; Freeman, A., CDC, CBA to Improve the Delivery and Effectiveness of HIV Prevention Services, $230,564; Garrard, W., NIH, Reorganization of Higher-Order Chromatin Structures During Igk Gene Activation, $245,250; Girard, L., NIH/Vanderbilt Univ. Med. Ctr., Molecular Signature of Lung Cancer, $27,942; Haller, R., NIH, Exercise Adaptations in Mitochondrial Myopathy: Therapeutic Implications, $484,600.
He, Y., NIH/Visual Art and Science, Home-Based Vision Testing System for DR, $40,856; Hiesinger, P. R., NIH/Baylor Coll. of Med., Molecular Studies of the Roles and Regulation of the v-ATPase VO Sector, $54,126; Johnson, J., NIH, Transcriptional Regulatory Control of Neuronal Cell Type Specification, $55,290 (Lai, H., fellow); Lee, W., NIH, HALT-C Trial, $4,642; Levine, Benjamin, NASA, Cardiac Atrophy and Diastolic Dysfunction During and After Long Duration Spaceflight, $166,021.
Levine, B., NIH/NSBRI, Team Leader Cardiovascular Alterations Team, $37,456; Lister, G., NIH/Boston Univ. Med. Ctr., Study of Attitudes and Factors Affecting Infant Care, $24,500; Mangelsdorf, D., NIH/Baylor Coll. of Med., Nuclear Receptors and Coregulators in Health and Disease, $108,000; Millner, L., DHHS/UTMB Galveston, Model State-Supported Are Health Education Centers, $85,169; Moe, O., NIH, H+-ATPase B-Subunit Dysfunction and Calcium Nephrolithiasis, $250,000.
Norgard, M., NIH, The RpoN-RpoS Regulatory Pathway in Borrelia Burgdorferi, $250,000; North, C., NIH, Psychoeducation of HCV and Alcohol Behaviors, $554,873; Okada, P., NIH/Children’s Research Inst., EMSC Targeted Issues Grant, $38,417; Otwinowski, Z., NIH/Northwestern Univ., Center for Structural Genomics of Infectious Diseases, $109,585; Parada, L., NIH/Mount Sinai School of Med., Neural Substrates of Appetitive Behavior in Mood and Motivation, $70,000.
Reilly, R., NIH, K-Mg-Citrate as a BP Lowering Agent in African Americans; Role of Natriuresis, $150,000; Richards, B., NIH/UTHSC Houston, Genetic Studies of Clubfoot, $19,195; Ross, E., NIH, G Protein-Coupled Receptors-Structure and Regulation, $24,999 (Supplement); Schatzle, J., NIH, Characterization of Murine CD244 Haplotypes with Divergent Function, $80,757 (supplement); Scheuermann, R., NIH/Northrop Grumman Info. System, Bioinformatics Integration Support Contract Phase II, $706,410.
Schneider, J., NIH, Microenvironmental Control of Progenitors in Organ Dysfunction and Repair, $821,000; Shay, J., NIH/Univ. of Nebraska Med. Ctr., SPORE in Gastrointestinal Cancer, $74,893; Taussig, R., NIH, Mechanism of Drug-Induced Adenylyl Cyclase Super-Sensitization, $175,000; Wakeland, E., NIH/Oklahoma Medical Research Fndtn., Candidate Causal Variants in Systemic Lupus Erythematosus, $920,864; Wright, W., NIH/Boston Biomedical Research Inst., Biomarkers for Therapy of FSHD, $54,150.
Yuan, D., NIH, Characterization of Murine CD244 Haplotypes With Divergent Function, $80,757; Zhang, C., NIH, Neurogenesis De Novo in the Adult Central Nervous System, $280,000.
Gabriel, V., International Assn. of Fire Fighters Burn Fndtn., Localization of Relaxin Receptors in Burn Scar Fibroblasts, $2,400; Mahendroo, M., Burroughs Wellcome Fund, Assessment of Cervical Ripening by Sodium Magnetic Resonance Imaging, $50,000; Rosen, M., Cancer Research Inst., The Role of Lysine Methylation in Regulating the Actin Cytoskeleton, $48,500 (Jia, D., fellow); Toto, R., Amer. Diabetes Assn., Novel Biomarkers for Predicting Response to Treatment in Diabetic Nephropathy, $173,913.
dollar amounts not available
Beshay, V., A Double-Blind, Randomized, Placebo- and Active-Controlled Efficacy and Safety Study of the Effects of Study Drug/Conjugated Estrogens Combinations on Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women; Carr, B., RNA Expression Analysis of Endometrial Biopsies Comparing Placebo, Study Drug/CE and Raloxifine; Carr, B., Evaluation of Changes in Mammographic Breast Density Associated With Study Drug/Conjugated Estrogens, Raloxifene and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3115A1-303-WW; Chin, K., Registry to Prospectively Evaluate Use of Study Drug in Patients With Pulmonary Arterial Hypertension.
De Lemos, J., A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Multinational Study for Evaluation of Efficacy and Safety of Study Drug Versus Warfarin in Subjects With Atrial Fibrillation – Effective Anticoagulation With Factor X, a Next Generation in Atrial Fibrillation; McPhaul, M., An Open-Label Study of the Efficacy and Safety of Study Drug in the Treatment of the Signs and Symptoms of Endogenous Cushing’s Syndrome; Pandya, A., An Open-Label, Seven-Month Study to Evaluate the Safety and Efficacy of Study Drug Ointment Formulation in Patients With Stage I or IIA Mycosis Fungoides Who Have Completed an Initial 12-Month Treatment With Study Drug But Without a Complete Response.
Ramos-Roman, M., A 26-Week, Multinational, Multicenter, Open-Labeled, Two-Arm, Parallel, Randomized, Treat-to-Target Trial Comparing Efficacy and Safety of Soluble Insulin Analogue Combination Once Daily Plus Meal-Time Insulin Aspart for the Remaining Meals Versus Basal-Bolus Treatment With Insulin Detemir Plus Meal-Time Insulin Aspart in Subjects With Type 1 Diabetes; Rohrich, R., A Randomized, Controlled, Phase 3 Study to Evaluate Safety and Efficacy of Study Agent (Artiss) to Adhere Tissues and Improve Wound Healing in Subjects Undergoing Rhytidectomy; Vernino, S., A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Induction-Design Study to Assess the Clinical Effect of Study Drug in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension.